InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell

MT Newswires Live05-28

InflaRx (IFRX) said Wednesday it plans to discontinue further development of vilobelimab for the treatment of pyoderma gangrenosum, a rare and inflammatory skin disease.

An independent data monitoring committee conducting an unblinded interim analysis for a phase 3 trial for vilobelimab recommended that the trial be stopped due to futility, the company said.

InflaRx said it intends to focus its resources on INF904, with phase 2a data readouts in chronic spontaneous urticaria and hidradenitis suppurativa expected this summer.

The company said it is also contemplating additional cost savings and redirection of resources, with a view to extending its existing cash runway

InflaRx shares were down nearly 51% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2538478550?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 19:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538478550","market":"nz","top_or_hot":-1,"title":"InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> InflaRx (IFRX) said Wednesday it plans to discontinue further development of vilobelimab for the treatment of pyoderma gangrenosum, a rare and inflammatory skin disease.</p><p>An independent data monitoring committee conducting an unblinded interim analysis for a phase 3 trial for vilobelimab recommended that the trial be stopped due to futility, the company said.</p><p>InflaRx said it intends to focus its resources on INF904, with phase 2a data readouts in chronic spontaneous urticaria and hidradenitis suppurativa expected this summer.</p><p>The company said it is also contemplating additional cost savings and redirection of resources, with a view to extending its existing cash runway</p><p>InflaRx shares were down nearly 51% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-28 19:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> InflaRx (IFRX) said Wednesday it plans to discontinue further development of vilobelimab for the treatment of pyoderma gangrenosum, a rare and inflammatory skin disease.</p><p>An independent data monitoring committee conducting an unblinded interim analysis for a phase 3 trial for vilobelimab recommended that the trial be stopped due to futility, the company said.</p><p>InflaRx said it intends to focus its resources on INF904, with phase 2a data readouts in chronic spontaneous urticaria and hidradenitis suppurativa expected this summer.</p><p>The company said it is also contemplating additional cost savings and redirection of resources, with a view to extending its existing cash runway</p><p>InflaRx shares were down nearly 51% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IFRX","symbol_name":"InflaRx N.V.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2538478550","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538478550","pubTimestamp":1748430996,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"InflaRx  said Wednesday it plans to discontinue further development of vilobelimab for the treatment of pyoderma gangrenosum, a rare and inflammatory skin disease.An independent data monitoring committee conducting an unblinded interim analysis for a phase 3 trial for vilobelimab recommended that the trial be stopped due to futility, the company said.InflaRx said it intends to focus its resources on INF904, with phase 2a data readouts in chronic spontaneous urticaria and hidradenitis suppurativa expected this summer.The company said it is also contemplating additional cost savings and redirection of resources, with a view to extending its existing cash runwayInflaRx shares were down nearly 51% in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IFRX":"InflaRx N.V.","BK4139":"生物科技"},"translate_title":"InflaRx将停止用于皮肤病治疗的Vilobelimab开发；盘前股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IFRX":0.9},"content_text":"InflaRx (IFRX) said Wednesday it plans to discontinue further development of vilobelimab for the treatment of pyoderma gangrenosum, a rare and inflammatory skin disease.An independent data monitoring committee conducting an unblinded interim analysis for a phase 3 trial for vilobelimab recommended that the trial be stopped due to futility, the company said.InflaRx said it intends to focus its resources on INF904, with phase 2a data readouts in chronic spontaneous urticaria and hidradenitis suppurativa expected this summer.The company said it is also contemplating additional cost savings and redirection of resources, with a view to extending its existing cash runwayInflaRx shares were down nearly 51% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2538478550","isCrawlerRequest":true}